Key result
Endothelin dual receptor blockade by bosentan improves quality of life, functional capacity, and pulmonary hemodynamics in patients with pulmonary hypertension.
Why the study?
Does bosentan improve quality of life, functional capacity, and pulmonary hemodynamics in patients with pulmonary hypertension?
Does bosentan improve quality of life, functional capacity, and pulmonary hemodynamics in patients with pulmonary hypertension?
Endothelin dual receptor blockade with bosentan provides clinical and hemodynamic benefits in patients with pulmonary hypertension.
Supports bosentan consideration in pulmonary hypertension; leaves open need for updated randomized trials.
Pulmonary hypertension is characterized by an increase in mean pulmonary arterial pressure and right ventricular overload. Endothelin-1 (ET-1) is a potent vasoconstrictor with an important role in the pathogenesis of pulmonary hypertension. In addition to its vasoconstrictive action, ET-1 also stimulates cell proliferation, fibrosis, and inflammation. The blockade of both receptors involved in the action of ET-1 is beneficial in the treatment of pulmonary hypertension. The use of endothelin dual receptor blockade leads to improvements in quality of life, functional capacity, and pulmonary hemodynamics in affected patients. This article reviews the importance of ET-1 in the pathogenesis of pulmonary hypertension and demonstrates the benefits of blockage of the action of ET-1 in this disease.
No takes yet. Share an insight, caveat, or question.
A 2010 study conducted a review in pulmonary hypertension. bosentan was evaluated. Endothelin dual receptor blockade by bosentan improves quality of life, functional capacity, and pulmonary hemodynamics in patients with pulmonary hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: